We power venture philanthropy
with the deep expertise, assets,
and data of the MMRF.
Our strategy is simple – leverage private capital to build a portfolio of financially attractive investments while advancing the needs of the myeloma community.
We rigorously source, vet, identify and invest in companies and organizations with profound potential to transform how multiple myeloma is treated by focusing on a portfolio of therapies and technologies, with a strong emphasis on those specializing in immuno-oncology.
We prioritize opportunities that will directly accelerate the state of multiple myeloma research and the needs of the multiple myeloma community by leveraging data and expertise from a wide array of sources.
As our investments start to see returns, we’ll continue to reinvest 100% of profits directly back into research for new treatments until we’ve successful delivered cures to all patients.
The Myeloma Investment Fund is a call to arms for philanthropists to help disrupt and de-risk investment in immuno-oncology through novel investment models as we push toward the cure for multiple myeloma, while simultaneously paving the way for future innovations and other novel investment opportunities. Structured like a private equity fund, the MIF has a minimum donation of $100,000. All private capital raised is recorded as a charitable donation and receives associated tax benefits at the time of contribution.